A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus

NCT ID: NCT05620407

This clinical trial is studying a new medication called deucravacitinib to see how effective and safe it is for people with active systemic lupus erythematosus (SLE), a condition that can cause inf...

Recruiting

Phase: PHASE3 Conditions: Systemic Lupus Erythematosus

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

NCT ID: NCT06311721

This clinical trial is studying a new treatment called ABP 234 and comparing it to an existing medication known as Keytruda® (pembrolizumab) for patients with advanced non-squamous non-small cell l...

Recruiting

Phase: PHASE3 Conditions: Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

NCT ID: NCT07100080

This clinical trial is studying a new drug called Izalontamab Brengitecan to see how well it works compared to a standard chemotherapy treatment (platinum-pemetrexed) for people with a specific typ...

Not yet recruiting

Phase: PHASE2 Conditions: Non-Small Cell Lung Cancer

Pan Tumor Rollover Study

NCT ID: NCT03899155

The Pan Tumor Rollover Study is a clinical trial focused on understanding the long-term safety of a cancer treatment called nivolumab, both on its own and in combination with other therapies. This ...

Recruiting

Phase: PHASE2 Conditions: Cancer

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

NCT ID: NCT05020236

The MagnetisMM-5 clinical trial is studying a new treatment option for people with relapsed or refractory multiple myeloma, a type of blood cancer. Researchers want to see if a medication called el...

Recruiting

Phase: PHASE3 Conditions: Multiple Myeloma

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

NCT ID: NCT05317416

This clinical trial is studying a new treatment called elranatamab to see if it is more effective than a standard treatment called lenalidomide for patients with newly diagnosed multiple myeloma wh...

Recruiting

Phase: PHASE3 Conditions: Multiple Myeloma

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

NCT ID: NCT06057402

This clinical trial is designed for individuals with Multiple Myeloma, a type of blood cancer, who have previously participated in a related study and found benefit from a treatment called elranata...

Recruiting

Phase: PHASE4 Conditions: Multiple Myeloma

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

NCT ID: NCT06074588

This clinical trial is studying a new treatment called sacituzumab tirumotecan for patients with advanced or metastatic non-small cell lung cancer (NSCLC) that has specific genetic changes, such as...

Recruiting

Phase: PHASE3 Conditions: Non-small Cell Lung Cancer (NSCLC)

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

NCT ID: NCT06140836

The TRIDENT-3 clinical trial is studying two medications, repotrectinib and crizotinib, to see how effective and safe they are for treating patients with a specific type of lung cancer called ROS1-...

Recruiting

Phase: PHASE3 Conditions: Carcinoma, Non-Small-Cell Lung

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT ID: NCT06152575

The MagnetisMM-32 clinical trial is studying a new medicine called elranatamab for people with multiple myeloma (MM), a type of blood cancer that has returned after previous treatments. The trial a...

Recruiting

Phase: PHASE3 Conditions: Multiple Myeloma

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

NCT ID: NCT06356129

This clinical trial is studying a new treatment for patients with a type of cancer called high-risk large B-cell lymphoma (LBCL). Researchers want to see if adding a medication called golcadomide t...

Recruiting

Phase: PHASE3 Conditions: Large B-cell Lymphoma

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT ID: NCT06158841

This clinical trial is studying a new treatment called ABBV-383 for adults with relapsed or refractory multiple myeloma, which is a type of blood cancer that affects plasma cells. The trial will co...

Recruiting

Phase: PHASE3 Conditions: Multiple Myeloma

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

NCT ID: NCT06846671

This clinical trial is studying a new treatment called BGB-16673 for patients with chronic lymphocytic leukemia (CLL) who have already received certain other treatments. The goal is to see how effe...

Recruiting

Phase: PHASE3 Conditions: Chronic Lymphocytic Leukemia, CLL

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

NCT ID: NCT04464226

This clinical trial is studying the continuation of a treatment called darolutamide for men with cancer who have already participated in previous studies using this medication. The goal is to provi...

Recruiting

Phase: PHASE3 Conditions: Cancer

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

NCT ID: NCT05458297

This clinical trial is studying a new treatment called zilovertamab vedotin for patients with certain types of B-cell lymphomas, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (...

Recruiting

Phase: PHASE2 Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma +2 more

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

NCT ID: NCT05609968

This clinical trial is studying two different treatment options for adults with metastatic non-small cell lung cancer (NSCLC) that has a specific marker called PD-L1, which is found in at least 50%...

Recruiting

Phase: PHASE3 Conditions: Carcinoma, Non-Small-Cell Lung

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

NCT ID: NCT06132958

This clinical trial is studying a new treatment called MK-2870, also known as sacituzumab tirumotecan, for women with endometrial cancer who have already received certain types of treatments. These...

Recruiting

Phase: PHASE3 Conditions: Endometrial Cancer

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

NCT ID: NCT06312176

This clinical trial is studying a new treatment option for patients with a specific type of breast cancer called hormone receptor positive and HER2 negative (HR+/HER2-). The researchers want to see...

Recruiting

Phase: PHASE3 Conditions: Breast Neoplasms

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

NCT ID: NCT06422143

This clinical trial is exploring a new treatment approach for patients with metastatic squamous non-small cell lung cancer (NSCLC). The study is testing whether adding a drug called sacituzumab tir...

Recruiting

Phase: PHASE3 Conditions: Non-small Cell Lung Cancer, NSCLC

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT ID: NCT06459180

This clinical trial is studying a treatment called sacituzumab tirumotecan for women with recurrent or metastatic cervical cancer, which means the cancer has come back or spread after initial treat...

Recruiting

Phase: PHASE3 Conditions: Cervical Cancer

Main Menu

Clinical Trials in Nagoya, Aichi

111 Active Trials Found in Nagoya

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Pan Tumor Rollover Study

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)